Noopept

A Russian dipeptide nootropic, far more potent by weight than piracetam, sold freely as a supplement-ish powder in the West. The default "beginner nootropic" recommendation on every forum for a decade.

Noopept is a synthetic dipeptide developed in Russia, structurally related to the racetam family but far more potent by weight. Its proposed mechanism is a combination of raised BDNF and NGF — growth factors supporting neuron survival and plasticity — plus a metabolite that resembles an endogenous neuropeptide associated with memory. Like the other Russian nootropics here, the mechanistic story is detailed and the human evidence behind it is thin and geographically confined.

Russian trials in cognitive impairment (post-concussion, vascular) report benefit; healthy-user enhancement data is essentially absent. Animal studies show neurotrophic effects (NGF/BDNF). The gap between forum enthusiasm and published healthy-human evidence is about as wide as it gets.

• Approved as a medicine in Russia for cognitive impairment following vascular or traumatic causes. Not approved anywhere in the West, where it is sold as a research chemical or, questionably, as a supplement.
• The central published trial is 53 patients with vascular or traumatic cognitive impairment, compared against piracetam rather than placebo. That is LIMITED evidence at very low certainty for impaired patients, and none at all for healthy users.
• No Western randomised controlled trial exists, and no independent replication of the original findings.
• There is no evidence for cognitive enhancement in healthy people.
• The BDNF and NGF findings come from animal work rather than from human measurement.
• FDA has sent warning letters over products marketing it with disease-treatment and cognitive claims — the enforcement theory being that such claims make them unapproved new drugs. That is narrower than a ruling on its ingredient status, and it is still the reason it cannot be sold the way it is sold.

Orally active, unlike the peptide nootropics, with a short half-life measured in tens of minutes and effects attributed to an active metabolite. The "thousand times more potent than piracetam" figure comes from animal effective-dose comparisons — no validated human potency ratio exists. What is true is that it is sold as bulk research-chemical powder, and bulk powders of unapproved drugs should not be consumed at all: identity, concentration and contaminants are unverified, and no measuring equipment fixes that.

Commonly reported: irritability, headache, sleep disruption at higher intakes; some users report emotional blunting with sustained use. No long-term safety data. The potency-per-milligram that makes it "efficient" also makes eyeballed powder dosing genuinely careless.

• Anyone pregnant or breastfeeding
• Anyone with uncontrolled hypertension
• Anyone with an anxiety disorder or sleep disorder, both of which are commonly reported as worsening
• Anyone considering bulk research-chemical powder at all — no consumer equipment makes an unverified powder safe

• No characterised interaction profile in Western literature.
• Stimulants, where additive effects on sleep and irritability are commonly reported.
• Anything sedating, on mechanistic grounds rather than evidence.

• Irritability, sleep disturbance and raised blood pressure — the adverse events actually recorded in the 53-patient trial. Everything else in circulation, including the "emotional blunting" reports, is forum anecdote.
• Blood pressure, on the same grounds as other stimulating nootropics.
• Whether any perceived benefit persists past the first weeks, since expectation effects are strong in this category.

No withdrawal syndrome is described. Reported effects fade within days. Since no controlled evidence establishes benefit in healthy people, there is no established effect to lose. Anyone who noticed sleep or irritability problems on it should find those resolve after stopping.

US: unscheduled, sold as a "dietary supplement" in a grey zone (it does not meet the legal definition). Prescription drug in Russia.

Papers about this compound, not proof of the claims above. A title says what was studied, which is sometimes a negative result or a different question entirely.

• Effects of noopept on ocular, pancreatic and renal histopathology in streptozotocin induced prepubertal diabetic rats
  Biotech Histochem, 2023
• Effect of nootropic dipeptide noopept on CA1 pyramidal neurons involves α7AChRs on interneurons in hippocampal slices from rat
  Neurosci Lett, 2022
• Noopept; a nootropic dipeptide, modulates persistent inflammation by effecting spinal microglia dependent Brain Derived Neurotropic Factor (BDNF) and pro-BDNF expression throughout apoptotic process
  Heliyon, 2021

• Cognitive Enhancer Noopept Activates Transcription Factor HIF-1Dokl Biochem Biophys · 2020
• Effects of noopept on ocular, pancreatic and renal histopathology in streptozotocin induced prepubertal diabetic ratsBiotech Histochem · 2023
• Drug with Neuroprotective Properties Noopept Does Not Stimulate Cell ProliferationBull Exp Biol Med · 2019
• Effects of noopept on cognitive functions and pubertal process in rats with diabetesLife Sci · 2019
• [The original novel nootropic and neuroprotective agent noopept]Eksp Klin Farmakol · 2002
• Neuroprotective Dipeptide Noopept Prevents DNA Damage in Mice with Modeled PrediabetesBull Exp Biol Med · 2019
• Noopept normalizes parameters of the incretin system in rats with experimental diabetesBull Exp Biol Med · 2014
• Noopept; a nootropic dipeptide, modulates persistent inflammation by effecting spinal microglia dependent Brain Derived Neurotropic Factor (BDNF) and pro-BDNF expression throughout apoptotic processHeliyon · 2021
• Effect of nootropic dipeptide noopept on CA1 pyramidal neurons involves α7AChRs on interneurons in hippocampal slices from ratNeurosci Lett · 2022
• Noopept Attenuates Diabetes-Mediated Neuropathic Pain and Oxidative Hippocampal Neurotoxicity via Inhibition of TRPV1 Channel in RatsMol Neurobiol · 2021
• Noopept stimulates the expression of NGF and BDNF in rat hippocampusBull Exp Biol Med · 2008
• [Pharmacokinetics of noopept and its active metabolite cycloprolyl glycine in rats]Biomed Khim · 2018